Effect of pre-loading oral glucosamine HCl/chondroitin sulfate/manganese ascorbate combination on experimental arthritis in rats.
The therapeutic effect of a nutritional supplement consisting of a combination of glucosamine hydrochloride (FCHG49), purified sodium chondroitin sulfate (TRH122), and manganese ascorbate (GCM)3 was investigated in the rat model of collagen-induced autoimmune arthritis (CIA). The GCM compound was mixed with a palatable nutritional paste (Nutri-cal [NC]). Oral administration of the NC/GCM compound was initiated in 26 rats 10 days before immunization and continued until the day of sacrifice. One group of 12 control rats was given no oral agents; a second group of 12 control rats received NC only. Evaluations included arthritis index (AI) scoring by three independent evaluators, histologic index (HI) scoring of lesions, T-cell proliferation, and serological studies for antibody classes and subclasses. Both the AI and HI criteria showed a statistically significant reduction in the prevalence of CIA in rats pretreated with the NC/GCM (54%) compared to the combined control groups (96%, chi2 analysis P = 0.001). Rats fed the NC/GCM also exhibited a significant decrease in the severity of autoimmune arthritis in both the AI and HI compared to control Group 2 (immunized-NC) (chi2 analysis P < 0.05). Histological studies verified the decreased incidence of arthritis in the NC/GCM group compared to control Group 2. GCM treatment failed to alter T-cell proliferation and antibody production to bovine type-II collagen, indicating that its effects are not due to alteration of the antigen-specific immune response.
Beren
J
J
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA.
Hill
S L
SL
Diener-West
M
M
Rose
N R
NR
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000139:chemically induced / Q000178:diet therapy*; D001205:Ascorbic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003094:Collagen / Q000276:immunology; D003676:Deferoxamine / Q000031:analogs & derivatives; D019587:Dietary Supplements; D004359:Drug Therapy, Combination; D005260:Female; D005944:Glucosamine / Q000627:therapeutic use; D007717:Knee / Q000473:pathology; D008345:Manganese / Q000627:therapeutic use*; D009942:Organometallic Compounds; D051381:Rats; D012720:Severity of Illness Index
D001323:Autoantibodies; D009942:Organometallic Compounds; C068338:manganese desferioxamine; D008345:Manganese; D002809:Chondroitin Sulfates; D003094:Collagen; D003676:Deferoxamine; D005944:Glucosamine; D001205:Ascorbic Acid